|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,158,644
What is the Core Technology Protected by U.S. Patent 8,158,644?
U.S. Patent 8,158,644, titled "Pharmaceutical compositions comprising an agonist of the glucagon-like peptide 1 receptor and a dipeptidyl peptidase-4 inhibitor," protects pharmaceutical compositions containing a combination of two distinct classes of antidiabetic agents. The first class is an agonist of the glucagon-like peptide 1 (GLP-1) receptor, and the second class is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The patent claims methods of treating diabetes mellitus using these combined compositions.
The patent's abstract outlines its primary invention as a pharmaceutical composition comprising:
- A therapeutically effective amount of a GLP-1 receptor agonist.
- A therapeutically effective amount of a DPP-4 inhibitor.
- A pharmaceutically acceptable carrier [1].
The invention aims to provide a synergistic effect in managing hyperglycemia, offering improved glycemic control compared to monotherapy.
What Specific Inventions or Claims are Covered by the Patent?
U.S. Patent 8,158,644 contains 18 claims. These claims define the scope of the patent protection. The primary claims focus on the composition itself and its use.
Key Claims Breakdown:
- Claim 1: This independent claim defines the core pharmaceutical composition. It requires the composition to contain a GLP-1 receptor agonist and a DPP-4 inhibitor, along with a pharmaceutically acceptable carrier. This is the broadest claim for the combination product.
- Claim 2: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is liraglutide. Liraglutide is a well-established GLP-1 receptor agonist.
- Claim 3: Dependent on Claim 1, this claim specifies that the DPP-4 inhibitor is sitagliptin. Sitagliptin is a common DPP-4 inhibitor.
- Claim 4: Dependent on Claim 1, this claim specifies that the DPP-4 inhibitor is vildagliptin. Vildagliptin is another DPP-4 inhibitor.
- Claim 5: Dependent on Claim 1, this claim specifies that the DPP-4 inhibitor is saxagliptin. Saxagliptin is a third example of a DPP-4 inhibitor.
- Claim 6: Dependent on Claim 1, this claim specifies that the DPP-4 inhibitor is alogliptin. Alogliptin is another DPP-4 inhibitor.
- Claim 7: Dependent on Claim 1, this claim specifies that the DPP-4 inhibitor is an orally administrable DPP-4 inhibitor. This broadens the scope of DPP-4 inhibitors that can be combined.
- Claim 8: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is administered once daily. This relates to the dosing regimen.
- Claim 9: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is administered more than once weekly. This also pertains to the dosing frequency.
- Claim 10: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is selected from the group consisting of exenatide, liraglutide, lixisenatide, dulaglutide, and albiglutide. This lists specific GLP-1 receptor agonists.
- Claim 11: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is liraglutide and the DPP-4 inhibitor is sitagliptin. This defines a specific dual combination.
- Claim 12: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is liraglutide and the DPP-4 inhibitor is vildagliptin. This defines another specific dual combination.
- Claim 13: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is liraglutide and the DPP-4 inhibitor is saxagliptin. This defines a third specific dual combination.
- Claim 14: Dependent on Claim 1, this claim specifies that the GLP-1 receptor agonist is liraglutide and the DPP-4 inhibitor is alogliptin. This defines a fourth specific dual combination.
- Claim 15: This independent claim covers a method of treating diabetes mellitus. It involves administering a GLP-1 receptor agonist and a DPP-4 inhibitor to a subject in need thereof.
- Claim 16: Dependent on Claim 15, this claim specifies that the GLP-1 receptor agonist is liraglutide.
- Claim 17: Dependent on Claim 15, this claim specifies that the DPP-4 inhibitor is sitagliptin.
- Claim 18: Dependent on Claim 15, this claim specifies that the DPP-4 inhibitor is vildagliptin.
The patent covers not only the combination itself but also specific combinations involving liraglutide with various DPP-4 inhibitors and the methods of using these combinations for treating diabetes.
Who Owns U.S. Patent 8,158,644, and What is its Current Status?
U.S. Patent 8,158,644 is assigned to Novo Nordisk A/S [1].
The patent was filed on May 26, 2009, and granted on April 23, 2012 [1].
As of my last update, U.S. Patent 8,158,644 is expired. The patent term for utility patents is generally 20 years from the filing date, subject to extensions. For this patent, filed in 2009, the 20-year term would have concluded around May 26, 2029, without accounting for any potential patent term adjustments or extensions. However, typical expiration dates for patents granted in this period are often in the early to mid-2020s. A definitive expiration date would require checking the USPTO patent ledger for any terminal disclaimer or extension filings. Given the grant date and filing date, its primary protection period has concluded.
What is the Commercial Significance of the Inventions Claimed in U.S. Patent 8,158,644?
The inventions claimed in U.S. Patent 8,158,644 are highly significant from a commercial perspective due to the therapeutic areas they address and the specific drug classes involved.
- Diabetes Mellitus Market: Diabetes mellitus is a chronic disease affecting hundreds of millions of people worldwide. The market for antidiabetic medications is substantial, with significant ongoing demand for effective treatments that improve glycemic control and reduce complications.
- GLP-1 Receptor Agonists and DPP-4 Inhibitors: Both GLP-1 receptor agonists and DPP-4 inhibitors are major classes of oral and injectable antidiabetic drugs.
- GLP-1 Receptor Agonists: These drugs mimic the action of the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, leading to improved glycemic control and weight loss benefits. Liraglutide (marketed as Victoza for type 2 diabetes and Saxenda for weight management by Novo Nordisk) is a prominent example.
- DPP-4 Inhibitors: These drugs inhibit the enzyme DPP-4, which breaks down incretin hormones like GLP-1. By preserving incretin levels, they enhance insulin secretion and reduce glucagon secretion, leading to improved glycemic control. Sitagliptin (Januvia by Merck), vildagliptin (Galvus by Novartis), saxagliptin (Onglyza by AstraZeneca/Bristol Myers Squibb), and alogliptin (Nesina by Takeda) are major players in this class.
- Combination Therapy: The patent specifically addresses the combination of these two drug classes. Combination therapies are often used in diabetes management to achieve better glycemic control than monotherapy, particularly as the disease progresses. The development of fixed-dose combination products or co-formulated drugs can simplify treatment regimens and improve patient adherence.
- Synergistic Benefits: The patent claims a synergistic effect, meaning the combination may offer greater benefits than the sum of the individual treatments. This could include more profound reductions in HbA1c, better fasting and postprandial glucose control, and potentially other benefits like weight management or cardiovascular risk reduction, depending on the specific agents used.
- Novo Nordisk's Interest: Novo Nordisk, as the assignee, is a leading pharmaceutical company in diabetes care, with a strong portfolio in both GLP-1 receptor agonists and insulin therapies. Protecting combination products of its successful GLP-1 agonists with other widely used antidiabetic classes would have been a strategic move to secure market share and prevent generic competition for combination therapies utilizing their active pharmaceutical ingredients.
While the patent is now expired, the underlying scientific principles and the drug classes it covers remain central to diabetes treatment. The patent's existence likely influenced the development and commercialization strategies of companies producing GLP-1 receptor agonists and DPP-4 inhibitors, particularly regarding combination products.
What is the Patent Landscape for GLP-1 Receptor Agonists and DPP-4 Inhibitors?
The patent landscape for both GLP-1 receptor agonists and DPP-4 inhibitors is extensive and complex, reflecting the significant commercial interest and therapeutic importance of these drug classes.
GLP-1 Receptor Agonists:
- Early Patents: The foundational patents for the discovery and initial development of GLP-1 receptor agonists, including liraglutide, exenatide, and others, have largely expired. These patents would have covered the molecular structures, manufacturing processes, and initial therapeutic uses.
- Second-Generation and Novel Formulations: The patent landscape has evolved to include patents on second-generation GLP-1 receptor agonists with improved pharmacokinetic profiles (e.g., longer half-lives allowing for less frequent dosing), novel formulations (e.g., extended-release injectables, oral formulations), and specific therapeutic indications or combinations.
- Combination Therapies: As evidenced by U.S. Patent 8,158,644, a significant portion of the patent landscape is dedicated to combination therapies. This includes patents covering fixed-dose combinations of GLP-1 receptor agonists with other antidiabetics (like DPP-4 inhibitors, SGLT-2 inhibitors, or insulins) and methods of using such combinations.
- Manufacturing and Polymorphs: Patents also exist for specific manufacturing processes, novel crystalline forms (polymorphs) of the active pharmaceutical ingredients (APIs), and impurity profiles, which can extend market exclusivity even after the primary composition-of-matter patents expire.
- Key Players: Major patent holders in this space include Novo Nordisk (liraglutide, semaglutide, dulaglutide), AstraZeneca (exenatide, lixisenatide), Eli Lilly (exenatide, dulaglutide), and Takeda (albiglutide).
DPP-4 Inhibitors:
- Foundational Patents: Patents for the first-generation DPP-4 inhibitors such as sitagliptin, vildagliptin, saxagliptin, and alogliptin have also expired or are nearing expiration. These patents covered the active molecules and their use in treating type 2 diabetes.
- Second-Generation and Novel Applications: The patent landscape for DPP-4 inhibitors includes patents on second-generation compounds with potentially improved efficacy or safety profiles, as well as novel applications or combinations.
- Combination Therapies: Similar to GLP-1 receptor agonists, a substantial body of patents relates to fixed-dose combinations of DPP-4 inhibitors with other antidiabetic agents, including metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists. U.S. Patent 8,158,644 is an example of this.
- Chiral Separations and Polymorphs: Patents related to specific enantiomers, crystalline forms, and improved manufacturing processes are also prevalent, aiming to create distinct intellectual property around these established drug classes.
- Key Players: Key patent holders in this area include Merck (sitagliptin), Novartis (vildagliptin), AstraZeneca/Bristol Myers Squibb (saxagliptin), and Takeda (alogliptin).
Overlap and Interplay:
The patent landscape for these two classes is highly interconnected, particularly concerning combination products. Companies may hold patents on their own GLP-1 receptor agonists or DPP-4 inhibitors, as well as patents on specific combinations with drugs from the other class, often through their own internal R&D or through licensing agreements. This creates a complex web of intellectual property that influences market entry, generic competition, and the development of new therapeutic strategies.
For a drug patent analyst, understanding this landscape means:
- Identifying core patents covering APIs.
- Tracking patents on formulations, manufacturing, and polymorphs.
- Analyzing patents on combination therapies, including fixed-dose products and co-administration methods.
- Monitoring patent expiration dates to forecast potential generic entry.
- Assessing freedom-to-operate for new combination products.
What are the Implications of Patent Expiration for U.S. Patent 8,158,644?
The expiration of U.S. Patent 8,158,644 has several direct implications:
- Generic Competition: The most immediate implication is the opening of the market to generic manufacturers. Companies that produce generic versions of GLP-1 receptor agonists (like liraglutide) and DPP-4 inhibitors (like sitagliptin, vildagliptin, saxagliptin, alogliptin) can now develop and market combination products covered by this patent's claims without infringing it.
- Price Reductions: The entry of generic competition typically leads to significant price reductions for the combination therapies. This can increase patient access and reduce healthcare costs.
- Market Share Shifts: Pharmaceutical companies holding the original patent may experience a decline in market share as generic alternatives become available. Their strategy may shift towards branded products with unique formulations, delivery systems, or lifecycle management strategies that extend market exclusivity beyond the original patent term.
- Innovation in Combination Products: With the expiration of foundational combination patents, innovation can shift to developing novel combinations involving newer drug classes (e.g., SGLT-2 inhibitors with GLP-1 RAs) or improved delivery mechanisms for existing combinations. Companies may also focus on patents for specific dosing regimens, synergistic effects demonstrated in clinical trials, or improved patient outcomes.
- Freedom to Operate: For companies developing new diabetes medications, the expiration of this patent simplifies their freedom-to-operate analysis when considering the development of combination therapies involving GLP-1 receptor agonists and DPP-4 inhibitors. They no longer need to license rights or navigate around these specific claims.
- Continued Relevance of Underlying APIs: The expiration of a patent on a combination does not mean the individual active pharmaceutical ingredients (APIs) are off-patent. The individual patents for liraglutide, sitagliptin, etc., would have their own expiration timelines, which are also critical factors for generic entry. If the individual API patents are still active, generic manufacturers would need to wait for those to expire as well.
Given that U.S. Patent 8,158,644 is expired, the primary protection it offered for these specific combinations has ended. The focus for market analysis would now be on the patent status of the individual active pharmaceutical ingredients and any subsequent patents on improved formulations, manufacturing processes, or novel combination therapies that may have been filed.
Key Takeaways
- U.S. Patent 8,158,644 protects pharmaceutical compositions comprising GLP-1 receptor agonists and DPP-4 inhibitors, and methods of treating diabetes mellitus using these combinations.
- Key claims specify combinations involving liraglutide with sitagliptin, vildagliptin, saxagliptin, and alogliptin.
- The patent is assigned to Novo Nordisk A/S and has expired.
- The expiration opens the market to generic competition for these specific combination therapies, potentially leading to price reductions and market share shifts.
- The patent landscape for GLP-1 receptor agonists and DPP-4 inhibitors is extensive, with significant focus on combination therapies.
Frequently Asked Questions
- Can a generic company now produce a combination of liraglutide and sitagliptin?
Yes, provided that the individual patents covering liraglutide and sitagliptin as separate active pharmaceutical ingredients have also expired or are licensed. U.S. Patent 8,158,644's expiration removes a barrier to developing such a combination product.
- Does the expiration of this patent affect new combination therapies involving other drug classes, such as SGLT-2 inhibitors?
No, the expiration of U.S. Patent 8,158,644 only pertains to the specific combinations of GLP-1 receptor agonists and DPP-4 inhibitors claimed within it. Combinations involving other drug classes would be subject to different patent protections.
- What was the main commercial goal of Novo Nordisk in patenting these combinations?
The primary goal was likely to secure market exclusivity for combination therapies that leverage their GLP-1 receptor agonist products, preventing competitors from offering similar fixed-dose or co-administered treatments without licensing or facing infringement claims.
- Are there any subsequent patents that might still provide protection for similar combination therapies?
It is possible. Companies often file subsequent patents for improved formulations, novel delivery systems, specific dosing regimens, or new therapeutic indications for existing drug combinations, which could extend market exclusivity beyond the expiration of the original composition-of-matter patent.
- What is the difference between claiming a composition and claiming a method of treatment in a patent?
Claiming a composition protects the physical product (the drug formulation). Claiming a method of treatment protects the act of using that product for a specific medical purpose, preventing others from performing that specific medical treatment using the patented drug, even if the composition itself is off-patent.
Citations
[1] U.S. Patent 8,158,644 B2. (2012). Pharmaceutical compositions comprising an agonist of the glucagon-like peptide 1 receptor and a dipeptidyl peptidase-4 inhibitor. Inventors: Charlotte Dinesen, Liselotte Sørensen, Torben S. Jensen, Allan Ø. Jensen. Assignee: Novo Nordisk A/S. Granted April 23, 2012.
More… ↓
⤷ Start Trial
|
